Chronic lymphocytic leukaemia: open trials in United Kingdom

33 open trials have a site in United Kingdom. Registry data; only the trial team decides who can take part.

NCT05947851
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
University College London Hospital-Cancer Clinical Trials Unit (Site 5001), London-Camden · City Hospital, Nottingham University Hospitals-Hematology (Site 5002), Nottingham
Registry updated 2026-11-06
NCT05091424
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Trial Treatment · Phase 1 · Hoffmann-La Roche
Christie Hospital NHS Trust, Manchester · Churchill Hospital, Oxford
Registry updated 2026-11-05
NCT06588478
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Trial Treatment · Phase 2 · Loxo Oncology, Inc.
Heartlands Hospital, Birmingham · The Beatson West of Scotland Cancer Centre, Glasgow · Northwick Park Hospital, Harrow · St James's University Hospital, Leeds · Lincoln County Hospital, Lincoln · Clatterbridge Cancer Centre - Liverpool, Liverpool · Hammersmith Hospital, London · Singleton Hospital, Swansea
Registry updated 2026-11-04
NCT06788509
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Trial Treatment · Phase 1 · Janssen Research & Development, LLC
University Hospitals of Leicester NHS Trust, Leicester · St Bartholomews Hospital, London · University Hospitals Plymouth NHS Trust, Plymouth
Registry updated 2026-11-04
NCT07218341
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Trial Treatment · Phase 4 · Eli Lilly and Company
Castle Hill Hospital, Hull · St James's University Hospital, Leeds · GenesisCare, Newmarket
Registry updated 2026-11-04
NCT07221500
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Trial Treatment · Phase 2 · Nurix Therapeutics, Inc.
Oxford University Hospitals NHS Foundation Trust, Headington · The Royal Marsden NHS Foundation Trust, London · Sarah Cannon Research Institute UK, Limited, London · The Christie NHS Foundation Trust, Manchester
Registry updated 2026-11-03
NCT06564038
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Trial Treatment · Phase 1/2 · AstraZeneca
Derriford · London · Oxford · Southampton
Registry updated 2026-10-28
NCT04728893
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Trial Treatment · Phase 2 · Merck Sharp & Dohme LLC
Bristol Haematology and Oncology Centre (Site 2610), Bristol · Sarah Cannon Research Institute UK (Site 2612), London · The Christie NHS Foundation Trust (Site 2602), Manchester · GenesisCare - Cambridge (Site 2611), Newmarket · Nottingham University Hospitals NHS Trust. City Hospital Campus (Site 2601), Nottingham · GenesisCare - Oxford (Site 2607), Oxford · The Royal Marsden NHS Foundation Trust. (Site 2606), Sutton · GenesisCare - Windsor (Site 2608), Windsor
Registry updated 2026-10-27
NCT06697184
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Trial Treatment · Phase 1/2 · BeOne Medicines
Queen Elizabeth Hospital, Birmingham · St Jamess University Hospital, Leeds
Registry updated 2026-10-26
NCT06943872
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Trial Treatment · Phase 3 · BeOne Medicines
University Hospitals Dorset Royal Bournemouth Hospital, Bournemouth · Oxford University Hospitals Nhs Trust Churchill Hospital, Headington · St Jamess University Hospital, Leeds · Kings College Hospital, London · Clatterbridge Cancer Centre, Metropolitan Borough of Wirral · Freeman Hospital, Newcastle upon Tyne · Royal Cornwall Hospitalsnhs Trust, Truro
Registry updated 2026-10-23
NCT07024706
MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
Trial Treatment · Phase 2 · AstraZeneca
Colchester · Derby · Edgbaston · Exeter · Leeds · London · Southampton
Registry updated 2026-10-23
NCT07648264
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Trial Treatment · Phase 3 · CSL Behring
Leicester Royal Infirmary, Leicester · Hammersmith Hospital, London · St. Bartholomew's Hospital, London
Registry updated 2026-10-14
NCT06136559
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Barnet Hospital (Site 3005), Barnet · GenesisCare - Bristol (Site 3011), Bristol · Southmead Hospital (Site 3010), Bristol · Royal Lancaster Infirmary (Site 3012), Lancaster · St James's University Hospital (Site 3004), Leeds · St Bartholomew's Hospital-Centre for Experimental Cancer Medicine (Site 3006), London · GenesisCare - Cambridge (Site 3001), Newmarket · City Hospital, Nottingham University Hospitals NHS Trust (Site 3003), Nottingham · The Churchill Hospital (Site 3007), Oxford · GenesisCare - Windsor (Site 3002), Windsor
Registry updated 2026-10-13
NCT03934372
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Trial Treatment · Phase 1/2 · Incyte Biosciences International Sàrl
Royal Hospital For Sick Children Yorkhill Glasgow, Glasgow · Alder Hey Childrens Nhs Foundation Trust, Liverpool · The Royal Marsden NHS Foundation Trust - Sutton, Sutton
Registry updated 2026-10-09
NCT07509151
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Trial Treatment · Phase 3 · AstraZeneca
Edinburgh · Hampshire · Leeds · London · Manchester · Nottingham · Oxford · Sutton
Registry updated 2026-10-06
NCT05006716
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Trial Treatment · Phase 1/2 · BeOne Medicines
Edinburgh Cancer Centre, Edinburgh · St Jamess University Hospital, Leeds · Freeman Hospital, Newcastle upon Tyne · Genesiscare Cambridge, Newmarket · Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich · Nottingham University Hospitals NHS Trust, Nottingham · Derriford Hospital, Plymouth
Registry updated 2026-10-05
NCT06846671
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Trial Treatment · Phase 3 · BeOne Medicines
Aberdeen Royal Infirmary, Aberdeen · Birmingham Heartlands Hospital, Birmingham · The Royal Bournemouth and Christchurch Hospitals Nhs Foundation, Bournemouth · Royal Marsden Hospital, London · University College Hospital, London · Southampton General Hospital, Southampton
Registry updated 2026-09-28
NCT06973187
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Trial Treatment · Phase 3 · BeOne Medicines
University Hospitals Sussex NHS Foundation Trust, Brighton · Kent and Canterbury Hospital, Canterbury · Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich · Oxford University Hospitals NHS Foundation Trust, Oxford · Spire Leeds Healthcare Spire Leeds Hospital, Roundhay · Salisbury Foundation Trust, Salisbury
Registry updated 2026-09-28
NCT07277231
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Trial Treatment · Phase 3 · BeOne Medicines
Queen Elizabeth Hospital, Birmingham · University Hospitals Dorset Royal Bournemouth Hospital, Bournemouth · St Jamess University Hospital, Leeds · Kings College Hospital, London · Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich
Registry updated 2026-09-28
NCT06651970
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
Trial Treatment · Phase 4 · AstraZeneca
Bournemouth · Oxford · Plymouth · Romford · Stockton · Sutton Coldfield
Registry updated 2026-09-24
NCT07463976
variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway
Research · The Royal Wolverhampton Hospitals NHS Trust
The Royal Wolverhampton NHS Trust, Wolverhampton
Registry updated 2026-09-15
NCT05557695
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
Research · AstraZeneca
Aylesbury · Bath · Birmingham · Bournemouth · Cardiff · Cornwall · Dartford · Derby · Doncaster · Dorset · Eastbourne · Hull · Leicester · Lincoln · Liverpool · London · Middlesbrough · Mid Yorkshire · Newcastle · North Shields · Norwich · Nottingham · Oxford · Plymouth · Southampton · Stockton-on-Tees · Stoke-on-Trent · Wigan
Registry updated 2026-09-09
NCT05254743
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Trial Treatment · Phase 3 · Loxo Oncology, Inc.
Bristol Haematology and Oncology Centre, Bristol · HOPE Centre, Leicester · St. Bartholomew's Hospital, London · Singleton Hospital, Swansea
Registry updated 2026-08-17
NCT06980116
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Trial Treatment · Phase 1 · Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
St James's University Hospital, Leeds · University Hospitals Plymouth NHS Trust, Derriford Hospital, Plymouth
Registry updated 2026-08-13
NCT05131022
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Trial Treatment · Phase 1 · Nurix Therapeutics, Inc.
The Beatson WOS Cancer Center, Glasgow · St James Hospital, Leeds · Clatterbridge Cancer Center NHS Foundation Trust, Liverpool · Sarah Cannon Research Institute UK, London · St. Bartholomew's Hospital, Barts NHS Trust, London · The Christie NHS Foundation Trust, Manchester · Oxford University Hospitals NHS Foundation Trust, Oxford · University Hospitals Plymouth NHS Trust, Plymouth · University Hospital Southampton NHS Foundation Trust, Southampton · Royal Marsden NHS Foundation Trust, Sutton
Registry updated 2026-07-02

All Chronic lymphocytic leukaemia trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error